🇲🇹Malta: Cell Companies and the MFSA Licensing Hub

Concept

A cell company is a Maltese corporate structure where multiple segregated cells operate under one license and one capital base. The core holds the MFSA authorization, while each cell conducts its own business with separate assets and liabilities, ring-fenced from other cells and from the core. For those building a regulated business, this is a way to launch insurance, fund, or payment activities without obtaining your own license: you rent the infrastructure and authorization of an already licensed core.

Malta has taken the model further than others: a cell gains direct access to EEA markets via passport—it is the only PCC jurisdiction within the EU with this capability. As a result, the island has become a European hub for cell insurance (captive and fronting), fund platforms, and also for neobank licenses, CASP under MiCA, and MGA gaming licenses.

Segregation is structured in two ways. PCC (Protected Cell Company) is a single legal entity: cells do not have separate legal personality, but their assets are protected by law from the liabilities of neighboring cells. This is how insurance works. ICC (Incorporated Cell Company)—each incorporated cell has its own legal personality and is licensed separately. This is how funds (SICAV ICC) and administrative platforms (RICC) operate.

🍓 Asset segregation holds as long as the structure holds. Recourse to the core, an undercapitalized cell, and cross-cell claims in a foreign court are three points where cell protection is tested for strength. Before launch, review the core's articles, its recourse policy, and how much the core is capitalized above the minimum.

How It Works

🔗 Related

delegated authority and fronting · third-party ManCo / AIFM

There are three parties. The core owns the license and capital, conducts due diligence on incoming cells, and is responsible to MFSA for the entire structure. The cell is the business owner who rents a cell for their risk or fund. MFSA licenses the core, and in the ICC model, also each cell.

In an insurance PCC, cells come in three types: captive cell (a group finances its own risk), fronting cell (captive owner reduces EEA fronting costs), and third-party writing cell (selling insurance to third parties). Under Solvency II, cells are recognized as ring-fenced funds, so minimum capital is calculated at the PCC level, not for each cell. We cover the mechanics of delegated authority and fronting separately—see delegated authority and fronting.

In a fund ICC, the logic is different: a SICAV ICC itself is licensed as a collective investment scheme, and its incorporated cells are each a separate CIS with its own license. RICC (Recognised Incorporated Cell Company) does not engage in licensable activities: it holds an MFSA Recognition Certificate and provides cells with an administrative platform, while each cell-fund obtains its own CIS license. The same principle of third-party infrastructure in EU funds—see third-party ManCo / AIFM.

What You Need to Launch

There are two paths: rent a cell in an existing PCC/ICC or establish your own core and lease out cells. The first is a fast and cheap entry; the second requires higher capital and operations, but gives control over the structure and income from tenant cells.

Capital. Under Solvency II, a notional capital is required at the cell level based on its own risk; an insurance PCC as a whole maintains an MCR (under Solvency II non-life floor—around €100K, in practice higher depending on lines). For a payment hub, separate thresholds apply: a neobank in Malta requires €350K. Your own core is capitalized substantially above the minimum—otherwise it cannot front and incubate the risk of incoming cells.

In addition to capital, you need: an agreement with the core (cell agreement) or incorporation of a cell in an ICC; local service providers—insurance manager, fund administrator, depositary, auditor; and an AML/CFT policy package required by both MFSA and the core itself when onboarding a cell.

Compliance

🔗 Related

embedded finance

Insurance falls under Solvency II: SCR and MCR, ORSA, actuarial function, regular reporting to MFSA; at the cell level—monitoring capital adequacy and recourse conditions to the core.

Funds fall under the CIS regime: depositary, audit, periodic reporting; for NAIF and PIF—specific requirements for the manager and investor due diligence.

The cross-cutting rule of the cluster applies here too: you can outsource activities, but not responsibility—the core is responsible to MFSA for the structure. The regulator checks whether the core actually controls the cells, rather than just renting out paper. This principle is the foundation of the entire license rental model (see embedded finance).

How It Works in the Market

🔗 Related

white-label under CASP license · casino master licenses

In insurance, cell platforms like Atlas Insurance PCC operate—one of the first independent PCCs in Malta. A risk owner enters a captive or fronting cell and saves on traditional fronting, which consumes around 7–10% of the premium. After Brexit, separate authorizations are needed to cover the EU and the UK, and a Maltese cell with an EEA passport is often cheaper.

In funds, the same role is played by SICAV ICC and RICC from local administrators. Separately, Malta issues rentable licenses outside cell structures: CASP under MiCA with an EU passport (white-label under CASP license) and MGA gaming licenses in white-label format (casino master licenses).

Deal terms: rental fee for the cell plus per-cell capital and share; in fronting—fronting fee and collateral for retained risk. When choosing a core, look at its capitalization and risk appetite, recourse policy, track record, and how quickly the core is ready to front new risk.

Applicable Regulation

Structure and capital requirements are with the regulator: MFSA — Authorisations and MFSA guide on Incorporated Cell Companies.

Pros and Cons

• Pro: EU/EEA passport directly from the cell—something offshore PCCs do not provide.
• Pro: asset segregation and lower capital than a standalone license; quick start.
• Pro: Solvency II recognizes cells as ring-fenced funds—capital is calculated at the core level.
• Minus: dependence on the license, capital, and reputation of the core.
• Minus: segregation is not absolute—a foreign court may not recognize cell protection, recourse to the core remains a risk.
• Minus: for your own core—high capital and operational burden; regulatory scrutiny of paper rental is tightening.